Cloning, overexpression, purification of bacteriocin enterocin-B and structural analysis, interaction determination of enterocin-A, B against pathogenic bacteria and human cancer cells

Ankaiah, Dasari; Esakkiraj, Palanichamy; Antonyraj, Christian Bharathi; Ayyanna, Repally; Venkatesh, Perumal; Ahamed, Syed Ibrahim Basheer; Arul, Venkatesan

doi:10.1016/j.ijbiomac.2018.05.002

Cited by 54 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many bacteriocins fulfil most criteria, including low MIC values, low immunogenicity and toxicity, and low potential to induce resistance, which encourage studies aimed at marketing them as clinically relevant compounds [6], [7], [8], [9]. Interestingly, some recent reports describe very potent bacteriocins produced by enterococci, such as enterocins A and B, produced by Enterococcus faecium [10], enterocins DD14 [11] and SL-5 [12], both identical to MR10A and MR10B [13], enterocin EntV [14] and even enterocin EF478 [15], which displays sequence similarity to a serine protease of Enterococcus faecalis . In no case has a thorough characterization of its therapeutic profile been conducted.…”

Section: Introductionmentioning

confidence: 99%

Preclinical studies of toxicity and safety of the AS-48 bacteriocin

Cebrián

Rodríguez-Cabezas

Martín‐Escolano

et al. 2019

Journal of Advanced Research

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Preclinical studies of toxicity and safety of the AS-48 bacteriocin

Cebrián

Rodríguez-Cabezas

Martín‐Escolano

et al. 2019

Journal of Advanced Research

View full text Add to dashboard Cite

show abstract

“…In agreement with these results, we also observed decreased susceptibility of SW620 cells to the bacteriocin-mediated cytotoxic effect, compared to HT29 cells. Additionally, the bacteriocin enterocin-B produced by Enterococcus faecium exhibited cytotoxic activity against HeLa, HT29, and other cancer cell lines, causing hallmark apoptotic morphological changes such as membrane blebbing, smaller nuclei, apoptotic body formation and nuclear fragmentation (Ankaiah et al, 2018).…”

Section: Resultsmentioning

confidence: 99%

Exploiting Zebrafish Xenografts for Testing the in vivo Antitumorigenic Activity of Microcin E492 Against Human Colorectal Cancer Cells

et al. 2020

View full text Add to dashboard Cite

One of the approaches to address cancer treatment is to develop new drugs not only to obtain compounds with less side effects, but also to have a broader set of alternatives to tackle the resistant forms of this pathology. In this regard, growing evidence supports the use of bacteria-derived peptides such as bacteriocins, which have emerged as promising anti-cancer molecules. In addition to test the activity of these molecules on cancer cells in culture, their in vivo antitumorigenic properties must be validated in animal models. Although the standard approach for such assays employs experiments in nude mice, at the initial stages of testing, the use of high-throughput animal models would permit rapid proof-of-concept experiments, screening a high number of compounds, and thus increasing the possibilities of finding new anti-cancer molecules. A validated and promising alternative animal model are zebrafish larvae harboring xenografts of human cancer cells. Here, we addressed the anti-cancer properties of the antibacterial peptide microcin E492 (MccE492), a bacteriocin produced by Klebsiella pneumoniae, showing that this peptide has a marked cytotoxic effect on human colorectal cancer cells in vitro. Furthermore, we developed a zebrafish xenograft model using these cells to test the antitumor effect of MccE492 in vivo, demonstrating that intratumor injection of this peptide significantly reduced the tumor cell mass. Our results provide, for the first time, evidence of the in vivo antitumoral properties of a bacteriocin tested in an animal model. This evidence strongly supports the potential of this bacteriocin for the development of novel anti-cancer therapies.

show abstract

“…Furthermore, antiviral activities have been reported against herpes simplex viruses (HSV-1 and HSV-2), polio virus (PV3), measles virus, and influenza virus [41,66]. Immunomodulatory and anticancer properties of enterocins have not been widely explored but may also be of potential interest [67][68][69].…”

Section: Discussionmentioning

confidence: 99%

Genome Mining for Antimicrobial Compounds in Wild Marine Animals-Associated Enterococci

et al. 2021

View full text Add to dashboard Cite

New ecosystems are being actively mined for new bioactive compounds. Because of the large amount of unexplored biodiversity, bacteria from marine environments are especially promising. Further, host-associated microbes are of special interest because of their low toxicity and compatibility with host health. Here, we identified and characterized biosynthetic gene clusters encoding antimicrobial compounds in host-associated enterococci recovered from fecal samples of wild marine animals remote from human-affected ecosystems. Putative biosynthetic gene clusters in the genomes of 22 Enterococcus strains of marine origin were predicted using antiSMASH5 and Bagel4 bioinformatic software. At least one gene cluster encoding a putative bioactive compound precursor was identified in each genome. Collectively, 73 putative antimicrobial compounds were identified, including 61 bacteriocins (83.56%), 10 terpenes (13.70%), and 2 (2.74%) related to putative nonribosomal peptides (NRPs). Two of the species studied, Enterococcus avium and Enterococcus mundtti, are rare causes of human disease and were found to lack any known pathogenic determinants but yet possessed bacteriocin biosynthetic genes, suggesting possible additional utility as probiotics. Wild marine animal-associated enterococci from human-remote ecosystems provide a potentially rich source for new antimicrobial compounds of therapeutic and industrial value and potential probiotic application.

show abstract

Cloning, overexpression, purification of bacteriocin enterocin-B and structural analysis, interaction determination of enterocin-A, B against pathogenic bacteria and human cancer cells

Cited by 54 publications

References 32 publications

Preclinical studies of toxicity and safety of the AS-48 bacteriocin

Preclinical studies of toxicity and safety of the AS-48 bacteriocin

Exploiting Zebrafish Xenografts for Testing the in vivo Antitumorigenic Activity of Microcin E492 Against Human Colorectal Cancer Cells

Genome Mining for Antimicrobial Compounds in Wild Marine Animals-Associated Enterococci

Contact Info

Product

Resources

About